Since SCLC is highly sensitive to cytotoxic chemotherapy, we hypothesized that patients with ES-SCLC and a poor PS may benefit from anti-PD-L1 antibody therapy because tumor shrinkage by anticancer agents is expected to improve PS and tumor immune responses. The gene discussed is CD274; the disease is neoplasm.